Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Rob van der Pluijm presented encouraging findings from TRAC II trial analyses of Triple Artemisinin Combination Therapies to the All-Party Parliamentary Group on Malaria & NTDs on March 19th in Westminster at the Houses of Parliament.

Group photo of Rob van der Pluijm and colleagues in Westminster © Credit: Andrea Stewart

Did you know? In the UK, members of parliament (MPs) from different political parties form All-Party Parliamentary Groups to discuss themes of particular importance to the UK government and its populace.

The APPG on malaria and NTDs gathered March 19 in Westminster; Jeremy Lefroy MP welcomed Rob van der Pluijm on behalf of MORU, the Tracking Resistance to Artemesinin Collaboration II and the Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project.

Rob presented encouraging findings from TRAC II and launch plans for DeTACT in Africa and Asia. The UK Department for International Development’s (DfID) Senior Global Health Advisor attended alongside colleagues from the Wellcome Trust, LSHTM, Imperial College and other malaria advocacy groups.

Pertinent questions included whether DeTACT was an innovative attempt at ‘global health preparedness’ for eventual drug resistance in Africa; whether the WHO and national health programmes in endemic countries were likely to recommend triple dose treatments soon enough to prevent or slow the impact of drug resistance; and how well Mefloquine was tolerated when part of the Triple ACT combination.

Read a summary of the Westminster event.

Photo: APPG on Malaria & NTDs Chair Jeremy Lefroy MP (right) and Catherine West MP (second right), together with Rob van der Pluijm (centre) and other research presenters from LSHTM and Nottingham University. Text and photo credit: Andrea Stewart.

Similar stories

Constant genetic surveillance necessary to keep multidrug-resistant malaria parasite strains in check, study finds

Continually monitoring malaria parasite populations is necessary to prevent outbreaks of previously dormant multidrug-resistant malaria strains, say University of Oxford researchers. Multidrug-resistant malaria parasite strains can rapidly grow or collapse in response to public health policy changes, say the researchers in a study published today in The Lancet.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

Combating drug-resistant malaria

MORU research has contributed to strategies to eliminate malaria in the Greater Mekong Sub-region, helping to prevent the spread of drug-resistant malaria and improving health provision and outcomes for remote communities.

Antimalarial chemoprophylaxis for forest goers could help accelerate malaria elimination in Cambodia

Giving people antimalarials during and after visiting the forest reduced their risk of contracting malaria 6-fold, and could be the missing piece towards eliminating malaria in Asia-Pacific and South America, say Mahidol and Oxford University researchers in a study published in The Lancet Infectious Diseases.

Call for researchers: Share your country’s national COVID-19 therapeutics guidelines

The joint MORU and IDDO Study to review global COVID-19 therapeutics guidelines, led by PIs Cintia V. Cruz, Mia Cokljat and Philippe Guérin, is examining current national COVID-19 treatment recommendations to investigate the level of variation and whether they are consistent with WHO guidelines for the pharmacological prevention and treatment of COVID-19.

Three new full Oxford Professors from MORU

Three MORU Network staff awarded full professorship at the Nuffield Department of Medicine, University of Oxford.